Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
sympathomimetic amine beta-2 adrenergic agonist |
| gptkbp:ATCCode |
R03AC14
|
| gptkbp:CASNumber |
37148-27-9
|
| gptkbp:category |
gptkb:veterinary_medicine
gptkb:phenylethanolamine amphetamine stimulant bronchodilator secondary alcohol beta-adrenergic agonist chlorobenzene derivative |
| gptkbp:chemicalFormula |
C12H18Cl2N2O
|
| gptkbp:discoveredBy |
1970s
|
| gptkbp:eliminationHalfLife |
36-48 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Clenbuterol
|
| gptkbp:IUPACName |
1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol
|
| gptkbp:KEGGID |
D07702
|
| gptkbp:legalStatus |
approved for veterinary use
banned in sports not approved for human use in the US |
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
277.19 g/mol
|
| gptkbp:notableCase |
athletes testing positive due to contaminated meat
|
| gptkbp:prohibits |
gptkb:World_Anti-Doping_Agency
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1426
2783 DB01407 |
| gptkbp:relatedTo |
gptkb:salbutamol
gptkb:albuterol terbutaline |
| gptkbp:riskFactor |
adverse cardiovascular effects
potential for misuse in bodybuilding |
| gptkbp:routeOfAdministration |
oral
inhalation |
| gptkbp:sideEffect |
anxiety
headache tachycardia cardiac hypertrophy muscle tremor |
| gptkbp:UNII |
XT1H2FLU9B
|
| gptkbp:used_in_veterinary_medicine_for |
treatment of respiratory diseases in horses
|
| gptkbp:usedFor |
treatment of asthma
bronchodilator performance enhancement (illicit) |
| gptkbp:bfsParent |
gptkb:34580-13-7
|
| gptkbp:bfsLayer |
6
|